International Journal of Molecular Medicine

International Journal of Molecular Medicine is a peer-reviewed open access journal published by Spandidos Publications since 1998 under the ISSN 1107-3756 and eISSN 1791-244X, covering molecular medicine and experimental research at the interface of basic and clinical medicine, with a 2025 Journal Impact Factor of 8.5 and a first quartile rank of 22 of 191 in medicine research and experimental《国际分子医学杂志》（International Journal of Molecular Medicine）是斯潘迪多斯出版社（Spandidos Publications）自 1998 年起出版的同行评审开放获取期刊，刊号 1107-3756、电子刊号 1791-244X，覆盖分子医学及基础与临床医学界面的实验研究，2025 年影响因子为 8.5，在医学研究与实验类 191 种期刊中列第 22 位、居第一四分位。

Scope

• The journal publishes original research, reviews and short communications on molecular medicine, emphasising studies that bridge basic molecular and cellular biology with clinical medicine and therapeutic development该刊刊载分子医学的原创研究、综述与短篇通讯，侧重连接基础分子与细胞生物学与临床医学及治疗开发的研究。
• It covers molecular and cellular mechanisms of human disease including cancer, cardiovascular disease, neurological and neurodegenerative disease, inflammatory and autoimmune disease, metabolic disease and infectious disease该刊覆盖人类疾病的分子与细胞机制，包括癌症、心血管疾病、神经与神经退行性疾病、炎症与自身免疫病、代谢病与感染病。
• The journal addresses gene expression and regulation, signal transduction, cell cycle, apoptosis, stem cell biology, epigenetics, non-coding ribonucleic acid and the molecular targets of therapeutic intervention该刊涉及基因表达与调控、信号转导、细胞周期、细胞凋亡、干细胞生物学、表观遗传学、非编码核糖核酸及治疗干预的分子靶点。
• It also covers experimental therapeutic approaches including gene therapy, cell therapy, nucleic acid based therapeutics, drug delivery and the preclinical evaluation of candidate therapeutics in cell and animal models该刊亦覆盖实验性治疗方法，包括基因治疗、细胞治疗、基于核酸的治疗、药物递送及候选治疗在细胞与动物模型中的临床前评价。
• As an open access journal it applies a Creative Commons licence to accepted articles and levies an article processing charge on the corresponding author, and it operates single-blind peer review作为开放获取期刊，该刊对录用文章采用知识共享许可，向通讯作者收取文章处理费，实行单盲同行评审。
• In the 2025 Journal Citation Reports it ranks 22 of 191 titles in medicine research and experimental with an 88.7 percentile and its five year indicator remains in the first quartile在 2025 年版期刊引证报告中，该刊在医学研究与实验类 191 种期刊中列第 22 位、百分位 88.7，五年指标同样位于第一四分位。

History

• The journal was launched in 1998 by Spandidos Publications as an open access title covering molecular medicine, and it has operated as a fully open access journal since its first volume该刊于 1998 年由斯潘迪多斯出版社（Spandidos Publications）创刊，作为分子医学的开放获取期刊，自第一卷起即为完全开放获取。
• It has been published monthly throughout most of its history, with twelve issues per volume per year, and it is one of the core titles of the Spandidos Publications portfolio该刊历史上大部分时间以月刊形式出版，每年一卷十二期，是斯潘迪多斯出版社（Spandidos Publications）期刊群的核心刊种之一。
• The Journal Impact Factor moved from 4.101 in 2021 to 5.314 in 2022, then to 5.8 in 2024 and to 8.5 in 2025, maintaining first quartile standing in medicine research and experimental throughout该刊影响因子由 2021 年的 4.101 升至 2022 年的 5.314，再升至 2024 年的 5.8 与 2025 年的 8.5，始终居医学研究与实验类第一四分位。
• The journal has progressively expanded its coverage to address non-coding ribonucleic acid, epigenetics, stem cell therapy, exosomes and the molecular mechanisms of therapy resistance, reflecting the molecular turn in medical research该刊逐步扩展覆盖以纳入非编码核糖核酸、表观遗传学、干细胞治疗、外泌体及治疗耐药的分子机制，反映医学研究的分子化转向。
• The publisher carries the journal on the Spandidos Publications platform and the digital object identifier prefix of its articles is 10.3892, shared with other Spandidos titles出版方将该刊载于斯潘迪多斯出版社（Spandidos Publications）平台，其文章的数字对象唯一标识符前缀为（10.3892），与斯潘迪多斯其他期刊一致。

Editors

• The journal is led by an editor-in-chief supported by an editorial board whose members are drawn from molecular medicine, cell biology, oncology, pharmacology and clinical medicine departments across the world该刊由一位主编带领，配以由世界各地分子医学、细胞生物学、肿瘤学、药理学与临床医学科系的学者组成的编委会。
• The editorial team includes associate editors responsible for subject areas such as cancer biology, cardiovascular and neurological disease, stem cells and regenerative medicine, and gene and cell therapy, reflecting the breadth of molecular medicine编辑团队设有副编辑，分别负责癌症生物学、心血管与神经疾病、干细胞与再生医学及基因与细胞治疗等方向，对应分子医学的广度。
• Editorial handling follows the Spandidos Publications editorial management system, with submissions assigned to handling editors based on subject expertise and competing interest declarations稿件处理依托斯潘迪多斯出版社（Spandidos Publications）的编辑管理系统，依据学科专长与利益冲突声明分配责任编辑。
• Peer review is single-blind and the journal maintains the Spandidos Publications standards on reviewer recruitment, conflict of interest management, data sharing and editorial independence同行评审采用单盲方式，该刊遵循斯潘迪多斯出版社（Spandidos Publications）在审稿人遴选、利益冲突管理、数据共享与编辑独立性方面的标准。
• The masthead and board roster are published on the journal page at the Spandidos Publications platform and updated as new members join or existing members step down编委名单在斯潘迪多斯出版社（Spandidos Publications）平台期刊页公布，并随成员增减而更新。